Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita

Dyskeratosis Congenita (DKC) is a systemic disorder caused by mutations resulting in impaired telomere maintenance. Clinical features include bone marrow failure and an increased risk of developing hematological malignancies. There are conflicting data whether androgen derivatives (AD) can elongate telomeres in vivo and whether AD treatment enhances the risk of gaining myelodysplastic syndrome‐related mutations. Seven TERC or TERT‐mutated DKC patients underwent AD treatment. All patients revealed hematological response. Telomere length of lymphocytes and granulocytes increased significantly and no MDS‐related mutations were detected. Pending longer follow‐up, treatment with AD seems to represent an efficient and safe therapy for DKC patients.

[1]  T. Brümmendorf,et al.  Comparison of flow‐FISH and MM–qPCR telomere length assessment techniques for the screening of telomeropathies , 2019, Annals of the New York Academy of Sciences.

[2]  S. Savage,et al.  Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. , 2018, Blood advances.

[3]  T. Brümmendorf,et al.  Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita , 2018, Leukemia.

[4]  P. Rosenberg,et al.  Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up , 2017, Haematologica.

[5]  T. Olson,et al.  Recent advances in understanding clonal haematopoiesis in aplastic anaemia , 2017, British journal of haematology.

[6]  B. Dumitriu,et al.  Danazol Treatment for Telomere Diseases. , 2016, The New England journal of medicine.

[7]  M. Blasco,et al.  Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres , 2015, Haematologica.

[8]  G. Mufti,et al.  Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. , 2014, Blood.

[9]  V. Plagnol,et al.  Constitutional Mutations in RTEL1 Cause Severe Dyskeratosis Congenita , 2013, American journal of human genetics.

[10]  K. Schwarz,et al.  Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation , 2012, Annals of Hematology.

[11]  D. Wallace,et al.  Telomere diseases. , 2010, The New England journal of medicine.

[12]  S. Kajigaya,et al.  Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. , 2009, Blood.

[13]  T. Brümmendorf,et al.  Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover , 2006, Leukemia.

[14]  K. Collins,et al.  Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita , 2004, Human Genetics.

[15]  T. Brümmendorf,et al.  Telomere length in leukocyte subpopulations of patients with aplastic anemia. , 2001, Blood.